Pulmonx
Jason Skinner is an experienced market development professional currently serving as the Market Development Manager EMEA at Pulmonx Corporation since April 2021. Prior roles at Boston Scientific included Senior Regional Manager and Key Account Manager, where responsibilities spanned cross-divisional sales management and direct account oversight in London. Prior to that, Jason was a Territory Manager at St. Jude Medical, providing sales and technical support across various hospitals in London and the surrounding regions. Jason's educational background includes a First Class Honours degree in Business Management from Oxford Brookes University and certifications in Cardiac Rhythm Device Therapy as well as leadership development programs at Boston Scientific.
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1